SCHEDULE 13G/A: Adage Capital Management Discloses 0.7% Stake in Lexeo Therapeutics
Beneficial Ownership Report
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has filed an amended Schedule 13G disclosing a beneficial ownership of 0.7% in Lexeo Therapeutics, Inc.'s common stock.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Lexeo Therapeutics, Inc.
- As of March 31, 2025, the Reporting Persons collectively beneficially own 237,953 shares of Lexeo Therapeutics, Inc. Common Stock.
- This ownership represents 0.7% of the total outstanding Common Stock of Lexeo Therapeutics, Inc.
- The percentage is calculated based on 33,196,997 shares of Common Stock outstanding as of March 21, 2025, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The shares are held with shared voting power and shared dispositive power by the Reporting Persons.
- The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the company. A 0.7% stake is not a controlling interest nor a major new investment.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by an institutional investor, Adage Capital Management, indicating its passive ownership stake in Lexeo Therapeutics. It does not provide specific insights into broader industry trends but reflects ongoing portfolio management by a significant investment firm within the biotechnology or pharmaceutical sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership structure and the holdings of a notable institutional investor, Adage Capital Management. The 0.7% stake is not significant enough to imply control or major influence.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Fiscal year end for Lexeo Therapeutics, Inc.'s Annual Report on Form 10-K. |
| 2025-03-21 | Date as of which 33,196,997 shares of Common Stock were outstanding, as reported in Lexeo Therapeutics' 10-K. |
| 2025-03-24 | Date Lexeo Therapeutics, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-05-12 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Lexeo Therapeutics, Adage Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.